Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) derivatives with Potent in vitro and in vivo Antimalarial Activity.

Xue L, Shi DH, Harjani JR, Huang F, Beveridge J, Dingjan T, Ban K, Diab S, Duffy S, Lucantoni L, Fletcher S, Chiu FCK, Blundell SA, Ellis K, Ralph SA, Wirjanata G, Teguh S, Noviyanti R, Chavchich M, Creek DJ, Price R, Marfurt J, Charman SA, Cuellar M, Strasser J, Dahlin J, Walters MA, Edstein M, Avery VM, Baell JB.

J Med Chem. 2019 Feb 4. doi: 10.1021/acs.jmedchem.8b01799. [Epub ahead of print]

PMID:
30715882
2.

Genomic analysis of Plasmodium vivax in southern Ethiopia reveals selective pressures in multiple parasite mechanisms.

Auburn S, Getachew S, Pearson RD, Amato R, Miotto O, Trimarsanto H, Zhu SJ, Rumaseb A, Marfurt J, Noviyanti R, Grigg MJ, Barber B, William T, Goncalves SM, Drury E, Sriprawat K, Anstey NM, Nosten F, Petros B, Aseffa A, McVean G, Kwiatkowski DP, Price RN.

J Infect Dis. 2019 Jan 21. doi: 10.1093/infdis/jiz016. [Epub ahead of print]

PMID:
30668735
3.

Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance.

Grigg MJ, William T, Piera KA, Rajahram GS, Jelip J, Aziz A, Menon J, Marfurt J, Price RN, Auburn S, Barber BE, Yeo TW, Anstey NM.

Malar J. 2018 Dec 10;17(1):463. doi: 10.1186/s12936-018-2593-x.

4.

Laboratory challenges of Plasmodium species identification in Aceh Province, Indonesia, a malaria elimination setting with newly discovered P. knowlesi.

Coutrier FN, Tirta YK, Cotter C, Zarlinda I, González IJ, Schwartz A, Maneh C, Marfurt J, Murphy M, Herdiana H, Anstey NM, Greenhouse B, Hsiang MS, Noviyanti R.

PLoS Negl Trop Dis. 2018 Nov 30;12(11):e0006924. doi: 10.1371/journal.pntd.0006924. eCollection 2018 Nov.

5.

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Gonzàlez Cabrera D, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01941-18. doi: 10.1128/AAC.01941-18. Print 2018 Nov. No abstract available.

6.

Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics.

Auburn S, Benavente ED, Miotto O, Pearson RD, Amato R, Grigg MJ, Barber BE, William T, Handayuni I, Marfurt J, Trimarsanto H, Noviyanti R, Sriprawat K, Nosten F, Campino S, Clark TG, Anstey NM, Kwiatkowski DP, Price RN.

Nat Commun. 2018 Jul 3;9(1):2585. doi: 10.1038/s41467-018-04965-4.

7.

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Cabrera DG, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00012-18. doi: 10.1128/AAC.00012-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Oct 24;62(11):.

PMID:
29941635
8.

Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.

Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, Ashley E, Baird JK, Gryseels C, Jambert E, Lacerda M, Laihad F, Marfurt J, Pasaribu AP, Poespoprodjo JR, Sutanto I, Taylor WR, van den Boogaard C, Battle KE, Dysoley L, Ghimire P, Hawley B, Hwang J, Khan WA, Mudin RNB, Sumiwi ME, Ahmed R, Aktaruzzaman MM, Awasthi KR, Bardaji A, Bell D, Boaz L, Burdam FH, Chandramohan D, Cheng Q, Chindawongsa K, Culpepper J, Das S, Deray R, Desai M, Domingo G, Duoquan W, Duparc S, Floranita R, Gerth-Guyette E, Howes RE, Hugo C, Jagoe G, Sariwati E, Jhora ST, Jinwei W, Karunajeewa H, Kenangalem E, Lal BK, Landuwulang C, Le Perru E, Lee SE, Makita LS, McCarthy J, Mekuria A, Mishra N, Naket E, Nambanya S, Nausien J, Duc TN, Thi TN, Noviyanti R, Pfeffer D, Qi G, Rahmalia A, Rogerson S, Samad I, Sattabongkot J, Satyagraha A, Shanks D, Sharma SN, Sibley CH, Sungkar A, Syafruddin D, Talukdar A, Tarning J, Ter Kuile F, Thapa S, Theodora M, Huy TT, Waramin E, Waramori G, Woyessa A, Wongsrichanalai C, Xa NX, Yeom JS, Hermawan L, Devine A, Nowak S, Jaya I, Supargiyono S, Grietens KP, Price RN.

Malar J. 2018 Jun 20;17(1):241. doi: 10.1186/s12936-018-2380-8.

9.

Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.

Hamid MMA, Thriemer K, Elobied ME, Mahgoub NS, Boshara SA, Elsafi HMH, Gumaa SA, Hamid T, Abdelbagi H, Basheir HM, Marfurt J, Chen I, Gosling R, Price RN, Ley B.

Malar J. 2018 Mar 16;17(1):117. doi: 10.1186/s12936-018-2266-9.

10.

The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes.

Tonkin-Hill GQ, Trianty L, Noviyanti R, Nguyen HHT, Sebayang BF, Lampah DA, Marfurt J, Cobbold SA, Rambhatla JS, McConville MJ, Rogerson SJ, Brown GV, Day KP, Price RN, Anstey NM, Papenfuss AT, Duffy MF.

PLoS Biol. 2018 Mar 12;16(3):e2004328. doi: 10.1371/journal.pbio.2004328. eCollection 2018 Mar.

11.

Therapeutic Response to Dihydroartemisinin-Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia.

Poespoprodjo JR, Kenangalem E, Wafom J, Chandrawati F, Puspitasari AM, Ley B, Trianty L, Korten Z, Surya A, Syafruddin D, Anstey NM, Marfurt J, Noviyanti R, Price RN.

Am J Trop Med Hyg. 2018 Mar;98(3):677-682. doi: 10.4269/ajtmh.17-0662. Epub 2018 Jan 11.

12.

Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection.

Pava Z, Handayuni I, Trianty L, Utami RAS, Tirta YK, Puspitasari AM, Burdam F, Kenangalem E, Wirjanata G, Kho S, Trimarsanto H, Anstey N, Poespoprodjo JR, Noviyanti R, Price RN, Marfurt J, Auburn S.

Am J Trop Med Hyg. 2017 Dec;97(6):1788-1796. doi: 10.4269/ajtmh.17-0364. Epub 2017 Aug 31.

13.

Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh.

Alam MS, Ley B, Nima MK, Johora FT, Hossain ME, Thriemer K, Auburn S, Marfurt J, Price RN, Khan WA.

Malar J. 2017 Aug 15;16(1):335. doi: 10.1186/s12936-017-1995-5.

14.

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.

O'Neill PM, Amewu RK, Charman SA, Sabbani S, Gnädig NF, Straimer J, Fidock DA, Shore ER, Roberts NL, Wong MH, Hong WD, Pidathala C, Riley C, Murphy B, Aljayyoussi G, Gamo FJ, Sanz L, Rodrigues J, Cortes CG, Herreros E, Angulo-Barturén I, Jiménez-Díaz MB, Bazaga SF, Martínez-Martínez MS, Campo B, Sharma R, Ryan E, Shackleford DM, Campbell S, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Palmer MJ, Copple IM, Mercer AE, Ruecker A, Delves MJ, Sinden RE, Siegl P, Davies J, Rochford R, Kocken CHM, Zeeman AM, Nixon GL, Biagini GA, Ward SA.

Nat Commun. 2017 May 24;8:15159. doi: 10.1038/ncomms15159.

15.

Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes.

Wirjanata G, Handayuni I, Prayoga P, Leonardo L, Apriyanti D, Trianty L, Wandosa R, Gobay B, Kenangalem E, Poespoprodjo JR, Noviyanti R, Kyle DE, Cheng Q, Price RN, Marfurt J.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00355-17. doi: 10.1128/AAC.00355-17. Print 2017 Aug.

16.

Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections.

Pava Z, Noviyanti R, Handayuni I, Trimarsanto H, Trianty L, Burdam FH, Kenangalem E, Utami RAS, Tirta YK, Coutrier F, Poespoprodjo JR, Price RN, Marfurt J, Auburn S.

PLoS One. 2017 May 12;12(5):e0177445. doi: 10.1371/journal.pone.0177445. eCollection 2017.

17.

Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine.

Rutledge GG, Marr I, Huang GKL, Auburn S, Marfurt J, Sanders M, White NJ, Berriman M, Newbold CI, Anstey NM, Otto TD, Price RN.

Emerg Infect Dis. 2017 Aug;23(8):1300-1307. doi: 10.3201/eid2308.161582. Epub 2017 Aug 15.

18.

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group.

Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, Sattabongkot J, Jambert E, Domingo GJ, Commons R, Auburn S, Marfurt J, Devine A, Aktaruzzaman MM, Sohel N, Namgay R, Drukpa T, Sharma SN, Sarawati E, Samad I, Theodora M, Nambanya S, Ounekham S, Mudin RN, Da Thakur G, Makita LS, Deray R, Lee SE, Boaz L, Danansuriya MN, Mudiyanselage SD, Chinanonwait N, Kitchakarn S, Nausien J, Naket E, Duc TN, Do Manh H, Hong YS, Cheng Q, Richards JS, Kusriastuti R, Satyagraha A, Noviyanti R, Ding XC, Khan WA, Swe Phru C, Guoding Z, Qi G, Kaneko A, Miotto O, Nguitragool W, Roobsoong W, Battle K, Howes RE, Roca-Feltrer A, Duparc S, Bhowmick IP, Kenangalem E, Bibit JA, Barry A, Sintasath D, Abeyasinghe R, Sibley CH, McCarthy J, von Seidlein L, Baird JK, Price RN.

Malar J. 2017 Apr 5;16(1):141. doi: 10.1186/s12936-017-1784-1. Review.

19.

Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia.

Pava Z, Burdam FH, Handayuni I, Trianty L, Utami RA, Tirta YK, Kenangalem E, Lampah D, Kusuma A, Wirjanata G, Kho S, Simpson JA, Auburn S, Douglas NM, Noviyanti R, Anstey NM, Poespoprodjo JR, Marfurt J, Price RN.

PLoS One. 2016 Oct 27;11(10):e0165340. doi: 10.1371/journal.pone.0165340. eCollection 2016.

20.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.

Le Bihan A, de Kanter R, Angulo-Barturen I, Binkert C, Boss C, Brun R, Brunner R, Buchmann S, Burrows J, Dechering KJ, Delves M, Ewerling S, Ferrer S, Fischli C, Gamo-Benito FJ, Gnädig NF, Heidmann B, Jiménez-Díaz MB, Leroy D, Martínez MS, Meyer S, Moehrle JJ, Ng CL, Noviyanti R, Ruecker A, Sanz LM, Sauerwein RW, Scheurer C, Schleiferboeck S, Sinden R, Snyder C, Straimer J, Wirjanata G, Marfurt J, Price RN, Weller T, Fischli W, Fidock DA, Clozel M, Wittlin S.

PLoS Med. 2016 Oct 4;13(10):e1002138. doi: 10.1371/journal.pmed.1002138. eCollection 2016 Oct.

21.

A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.

Phillips MA, White KL, Kokkonda S, Deng X, White J, El Mazouni F, Marsh K, Tomchick DR, Manjalanagara K, Rudra KR, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Shackleford DM, Chiu FC, Campbell M, Jimenez-Diaz MB, Bazaga SF, Angulo-Barturen I, Martinez MS, Lafuente-Monasterio M, Kaminsky W, Silue K, Zeeman AM, Kocken C, Leroy D, Blasco B, Rossignol E, Rueckle T, Matthews D, Burrows JN, Waterson D, Palmer MJ, Rathod PK, Charman SA.

ACS Infect Dis. 2016 Dec 9;2(12):945-957. Epub 2016 Oct 4.

22.

Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life.

Burdam FH, Hakimi M, Thio F, Kenangalem E, Indrawanti R, Noviyanti R, Trianty L, Marfurt J, Handayuni I, Soenarto Y, Douglas NM, Anstey NM, Price RN, Poespoprodjo JR.

PLoS One. 2016 Aug 9;11(8):e0160917. doi: 10.1371/journal.pone.0160917. eCollection 2016.

23.

Transfusion-transmitted severe Plasmodium knowlesi malaria in a splenectomized patient with beta-thalassaemia major in Sabah, Malaysia: a case report.

Bird EM, Parameswaran U, William T, Khoo TM, Grigg MJ, Aziz A, Marfurt J, Yeo TW, Auburn S, Anstey NM, Barber BE.

Malar J. 2016 Jul 12;15(1):357. doi: 10.1186/s12936-016-1398-z.

24.

Genomic analysis of local variation and recent evolution in Plasmodium vivax.

Pearson RD, Amato R, Auburn S, Miotto O, Almagro-Garcia J, Amaratunga C, Suon S, Mao S, Noviyanti R, Trimarsanto H, Marfurt J, Anstey NM, William T, Boni MF, Dolecek C, Hien TT, White NJ, Michon P, Siba P, Tavul L, Harrison G, Barry A, Mueller I, Ferreira MU, Karunaweera N, Randrianarivelojosia M, Gao Q, Hubbart C, Hart L, Jeffery B, Drury E, Mead D, Kekre M, Campino S, Manske M, Cornelius VJ, MacInnis B, Rockett KA, Miles A, Rayner JC, Fairhurst RM, Nosten F, Price RN, Kwiatkowski DP.

Nat Genet. 2016 Aug;48(8):959-964. doi: 10.1038/ng.3599. Epub 2016 Jun 27.

25.

Characterization of blood dendritic and regulatory T cells in asymptomatic adults with sub-microscopic Plasmodium falciparum or Plasmodium vivax infection.

Kho S, Marfurt J, Handayuni I, Pava Z, Noviyanti R, Kusuma A, Piera KA, Burdam FH, Kenangalem E, Lampah DA, Engwerda CR, Poespoprodjo JR, Price RN, Anstey NM, Minigo G, Woodberry T.

Malar J. 2016 Jun 21;15:328. doi: 10.1186/s12936-016-1382-7.

26.

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.

Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A, Upton LM, Abraham TS, Almeida MJ, Pradhan A, Porzelle A, Martínez MS, Bolscher JM, Woodland A, Luksch T, Norval S, Zuccotto F, Thomas J, Simeons F, Stojanovski L, Osuna-Cabello M, Brock PM, Churcher TS, Sala KA, Zakutansky SE, Jiménez-Díaz MB, Sanz LM, Riley J, Basak R, Campbell M, Avery VM, Sauerwein RW, Dechering KJ, Noviyanti R, Campo B, Frearson JA, Angulo-Barturen I, Ferrer-Bazaga S, Gamo FJ, Wyatt PG, Leroy D, Siegl P, Delves MJ, Kyle DE, Wittlin S, Marfurt J, Price RN, Sinden RE, Winzeler EA, Charman SA, Bebrevska L, Gray DW, Campbell S, Fairlamb AH, Willis PA, Rayner JC, Fidock DA, Read KD, Gilbert IH.

Nature. 2016 Sep 1;537(7618):122. doi: 10.1038/nature18280. Epub 2016 May 25. No abstract available.

27.

Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria.

Duffy MF, Noviyanti R, Tsuboi T, Feng ZP, Trianty L, Sebayang BF, Takashima E, Sumardy F, Lampah DA, Turner L, Lavstsen T, Fowkes FJ, Siba P, Rogerson SJ, Theander TG, Marfurt J, Price RN, Anstey NM, Brown GV, Papenfuss AT.

Malar J. 2016 May 5;15(1):258. doi: 10.1186/s12936-016-1296-4.

28.

Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms.

Wirjanata G, Handayuni I, Zaloumis SG, Chalfein F, Prayoga P, Kenangalem E, Poespoprodjo JR, Noviyanti R, Simpson JA, Price RN, Marfurt J.

Malar J. 2016 Mar 2;15:137. doi: 10.1186/s12936-016-1173-1.

29.

Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia.

Grigg MJ, Barber BE, Marfurt J, Imwong M, William T, Bird E, Piera KA, Aziz A, Boonyuen U, Drakeley CJ, Cox J, White NJ, Cheng Q, Yeo TW, Auburn S, Anstey NM.

PLoS One. 2016 Mar 1;11(3):e0149519. doi: 10.1371/journal.pone.0149519. eCollection 2016.

30.

Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility.

Pava Z, Handayuni I, Wirjanata G, To S, Trianty L, Noviyanti R, Poespoprodjo JR, Auburn S, Price RN, Marfurt J.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):361-7. doi: 10.1128/AAC.02207-15. Print 2016 Jan.

31.

Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry.

Wirjanata G, Handayuni I, Prayoga P, Apriyanti D, Chalfein F, Sebayang BF, Kho S, Noviyanti R, Kenangalem E, Campo B, Poespoprodjo JR, Price RN, Marfurt J.

Malar J. 2015 Oct 24;14:417. doi: 10.1186/s12936-015-0940-8.

32.

Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.

Wirjanata G, Sebayang BF, Chalfein F, Prayoga, Handayuni I, Trianty L, Kenangalem E, Noviyanti R, Campo B, Poespoprodjo JR, Möhrle JJ, Price RN, Marfurt J.

Antimicrob Agents Chemother. 2015 Oct;59(10):6117-24. doi: 10.1128/AAC.00874-15. Epub 2015 Jul 20.

33.

Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates.

Wirjanata G, Sebayang BF, Chalfein F, Prayoga, Handayuni I, Noviyanti R, Kenangalem E, Poespoprodjo JR, Burgess SJ, Peyton DH, Price RN, Marfurt J.

Antimicrob Agents Chemother. 2015 Sep;59(9):5721-6. doi: 10.1128/AAC.01048-15. Epub 2015 Jul 6.

34.

A novel multiple-stage antimalarial agent that inhibits protein synthesis.

Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A, Upton LM, Abraham TS, Almeida MJ, Pradhan A, Porzelle A, Luksch T, Martínez MS, Luksch T, Bolscher JM, Woodland A, Norval S, Zuccotto F, Thomas J, Simeons F, Stojanovski L, Osuna-Cabello M, Brock PM, Churcher TS, Sala KA, Zakutansky SE, Jiménez-Díaz MB, Sanz LM, Riley J, Basak R, Campbell M, Avery VM, Sauerwein RW, Dechering KJ, Noviyanti R, Campo B, Frearson JA, Angulo-Barturen I, Ferrer-Bazaga S, Gamo FJ, Wyatt PG, Leroy D, Siegl P, Delves MJ, Kyle DE, Wittlin S, Marfurt J, Price RN, Sinden RE, Winzeler EA, Charman SA, Bebrevska L, Gray DW, Campbell S, Fairlamb AH, Willis PA, Rayner JC, Fidock DA, Read KD, Gilbert IH.

Nature. 2015 Jun 18;522(7556):315-20. doi: 10.1038/nature14451. Erratum in: Nature. 2016 Sep 1;537(7618):122.

35.

Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection.

Kho S, Marfurt J, Noviyanti R, Kusuma A, Piera KA, Burdam FH, Kenangalem E, Lampah DA, Engwerda CR, Poespoprodjo JR, Price RN, Anstey NM, Minigo G, Woodberry T.

Infect Immun. 2015 Aug;83(8):3224-32. doi: 10.1128/IAI.00226-15. Epub 2015 Jun 1.

36.

Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination.

Noviyanti R, Coutrier F, Utami RA, Trimarsanto H, Tirta YK, Trianty L, Kusuma A, Sutanto I, Kosasih A, Kusriastuti R, Hawley WA, Laihad F, Lobo N, Marfurt J, Clark TG, Price RN, Auburn S.

PLoS Negl Trop Dis. 2015 May 7;9(5):e0003739. doi: 10.1371/journal.pntd.0003739. eCollection 2015 May.

37.

Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.

Vaidya AB, Morrisey JM, Zhang Z, Das S, Daly TM, Otto TD, Spillman NJ, Wyvratt M, Siegl P, Marfurt J, Wirjanata G, Sebayang BF, Price RN, Chatterjee A, Nagle A, Stasiak M, Charman SA, Angulo-Barturen I, Ferrer S, Belén Jiménez-Díaz M, Martínez MS, Gamo FJ, Avery VM, Ruecker A, Delves M, Kirk K, Berriman M, Kortagere S, Burrows J, Fan E, Bergman LW.

Nat Commun. 2014 Nov 25;5:5521. doi: 10.1038/ncomms6521.

38.

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.

Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, Chen Z, Francek C, Wu T, Nagle A, Barnes SW, Plouffe D, Lee MC, Fidock DA, Graumans W, van de Vegte-Bolmer M, van Gemert GJ, Wirjanata G, Sebayang B, Marfurt J, Russell B, Suwanarusk R, Price RN, Nosten F, Tungtaeng A, Gettayacamin M, Sattabongkot J, Taylor J, Walker JR, Tully D, Patra KP, Flannery EL, Vinetz JM, Renia L, Sauerwein RW, Winzeler EA, Glynne RJ, Diagana TT.

Antimicrob Agents Chemother. 2014 Sep;58(9):5060-7. doi: 10.1128/AAC.02727-13. Epub 2014 Jun 9.

39.

Quinolone-3-diarylethers: a new class of antimalarial drug.

Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CHM, Price RN, Avery VM, Angulo-Barturen I, Jiménez-Díaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK.

Sci Transl Med. 2013 Mar 20;5(177):177ra37. doi: 10.1126/scitranslmed.3005029.

40.

Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing.

Auburn S, Marfurt J, Maslen G, Campino S, Ruano Rubio V, Manske M, Machunter B, Kenangalem E, Noviyanti R, Trianty L, Sebayang B, Wirjanata G, Sriprawat K, Alcock D, Macinnis B, Miotto O, Clark TG, Russell B, Anstey NM, Nosten F, Kwiatkowski DP, Price RN.

PLoS One. 2013;8(1):e53160. doi: 10.1371/journal.pone.0053160. Epub 2013 Jan 4.

41.

A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy.

Barber BE, William T, Grigg MJ, Menon J, Auburn S, Marfurt J, Anstey NM, Yeo TW.

Clin Infect Dis. 2013 Feb;56(3):383-97. doi: 10.1093/cid/cis902. Epub 2012 Oct 19. Erratum in: Clin Infect Dis. 2014 Feb;58(4):608.

PMID:
23087389
42.

Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.

Price RN, Auburn S, Marfurt J, Cheng Q.

Trends Parasitol. 2012 Nov;28(11):522-9. doi: 10.1016/j.pt.2012.08.005. Epub 2012 Oct 5. Review.

43.

An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing.

Kerlin DH, Boyce K, Marfurt J, Simpson JA, Kenangalem E, Cheng Q, Price RN, Gatton ML.

PLoS Negl Trop Dis. 2012;6(8):e1772. doi: 10.1371/journal.pntd.0001772. Epub 2012 Aug 7.

44.

Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax.

Marfurt J, Chalfein F, Prayoga P, Wabiser F, Wirjanata G, Sebayang B, Piera KA, Wittlin S, Haynes RK, Möhrle JJ, Anstey NM, Kenangalem E, Price RN.

Antimicrob Agents Chemother. 2012 Oct;56(10):5258-63. doi: 10.1128/AAC.00283-12. Epub 2012 Jul 30.

45.

Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax.

Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, Machunter B, Tjitra E, Anstey NM, Price RN.

Antimicrob Agents Chemother. 2011 Sep;55(9):4461-4. doi: 10.1128/AAC.01375-10. Epub 2011 Jul 5.

46.

Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.

Marfurt J, Chalfein F, Prayoga P, Wabiser F, Kenangalem E, Piera KA, Fairlie DP, Tjitra E, Anstey NM, Andrews KT, Price RN.

Antimicrob Agents Chemother. 2011 Mar;55(3):961-6. doi: 10.1128/AAC.01220-10. Epub 2010 Dec 6.

47.

In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.

Siswantoro H, Russell B, Ratcliff A, Prasetyorini B, Chalfein F, Marfurt J, Kenangalem E, Wuwung M, Piera KA, Ebsworth EP, Anstey NM, Tjitra E, Price RN.

Antimicrob Agents Chemother. 2011 Jan;55(1):197-202. doi: 10.1128/AAC.01122-10. Epub 2010 Oct 11.

48.

Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology.

Ballif M, Hii J, Marfurt J, Crameri A, Fafale A, Felger I, Beck HP, Genton B.

Malar J. 2010 Oct 6;9:270. doi: 10.1186/1475-2875-9-270.

49.

In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.

Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, Tjitra E, Anstey NM, Russell B.

Antimicrob Agents Chemother. 2010 Dec;54(12):5146-50. doi: 10.1128/AAC.00801-10. Epub 2010 Sep 27.

50.

Plasmodium falciparum resistance to anti-malarial drugs in Papua New Guinea: evaluation of a community-based approach for the molecular monitoring of resistance.

Marfurt J, Smith TA, Hastings IM, Müller I, Sie A, Oa O, Baisor M, Reeder JC, Beck HP, Genton B.

Malar J. 2010 Jan 7;9:8. doi: 10.1186/1475-2875-9-8.

Supplemental Content

Loading ...
Support Center